Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.

Journal of pediatric gastroenterology and nutrition·2024
Same author

Dye-based chromoendoscopy detects more neoplasia than white light endoscopy in patients with primary sclerosing cholangitis and IBD.

Endoscopy international open·2024
Same author

A different picture on liver biopsy.

Journal of hepatology·2024
Same author

Primary sclerosing cholangitis-A long night's journey into day.

Clinical liver disease·2022
Same author

Results of a Model of Delivering Hepatitis C Care in a Homeless Metropolitan Population in England.

The American journal of gastroenterology·2022
Same author

Severe alcohol-related liver disease admissions post-COVID-19 lockdown: canary in the coal mine?

Frontline gastroenterology·2021

Related Experiment Video

Updated: May 27, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

Primary sclerosing cholangitis: is any treatment worthwhile?

Ashley Barnabas1, Roger W Chapman

  • 1Translational Gastroenterology unit, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DU, UK. abarnabas@nhs.net

Current Gastroenterology Reports
|November 30, 2011
PubMed
Summary

Primary Sclerosing Cholangitis (PSC) lacks proven disease-modifying therapies. Current treatments focus on managing complications, with liver transplantation offering a good outcome for end-stage disease.

Related Experiment Videos

Last Updated: May 27, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

Area of Science:

  • Gastroenterology and Hepatology
  • Cholestatic Liver Diseases
  • Autoimmune Liver Diseases

Background:

  • Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver disease with no approved therapies to alter its course.
  • Ursodeoxycholic acid (UDCA) is commonly used but its efficacy in PSC remains debated.
  • Distinguishing PSC from IgG4-associated cholangitis is crucial for appropriate treatment selection.

Purpose of the Study:

  • To review current therapeutic strategies for Primary Sclerosing Cholangitis.
  • To discuss the controversial role of ursodeoxycholic acid (UDCA) in PSC management.
  • To highlight the importance of managing complications and considering liver transplantation.

Main Methods:

  • Review of existing literature on PSC treatment modalities.
  • Analysis of the evidence supporting ursodeoxycholic acid (UDCA) use.
  • Discussion of diagnostic considerations, including exclusion of IgG4-associated cholangitis.
  • Evaluation of strategies for managing PSC complications and end-stage disease.

Main Results:

  • No therapeutic agents have demonstrated disease modification in controlled PSC trials.
  • Ursodeoxycholic acid (UDCA) may offer chemoprotection for associated inflammatory bowel disease.
  • Endoscopic management of dominant biliary strictures can improve long-term outcomes.
  • Orthotopic liver transplantation provides favorable outcomes for end-stage PSC.

Conclusions:

  • Effective disease-modifying treatments for PSC are still lacking.
  • Management focuses on addressing complications and supportive care.
  • Liver transplantation remains a critical option for patients with advanced PSC.